Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. MCK
MCK logo

MCK Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy McKesson Corp (MCK) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
928.690
1 Day change
-1.43%
52 Week Range
999.000
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

McKesson Corp (MCK) is not an optimal buy for a beginner investor with a long-term strategy at this time. While the company has strong financial performance and positive analyst ratings, the stock is currently trading at a premium, insider selling has increased significantly, and recent news about the CFO transition has negatively impacted sentiment. Additionally, technical indicators suggest a lack of clear upward momentum, and no Intellectia Proprietary Trading Signals are present to indicate a strong buy opportunity. It is advisable to monitor the stock for a better entry point.

Technical Analysis

The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 32.164, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is near its support level of 932.046, with resistance at 962.208. Pre-market price is down 0.79%, suggesting weak short-term sentiment.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The put-call ratios suggest a slightly bullish sentiment, but the implied volatility (27.15) and IV percentile (62.15) indicate moderate risk. Option volume is above the 30-day average, showing increased activity.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
6

Positive Catalysts

  • Strong Q3 financial performance with revenue up 11.40% YoY, net income up 34.93% YoY, and EPS up 38.18% YoY. Analysts have raised price targets, with the highest being $1,107, citing strong execution in core segments.

Neutral/Negative Catalysts

  • Insider selling has increased by 144.45% in the last month. Recent news of CFO Britt Vitalone's retirement has caused a 5.5% drop in share price. The stock is trading at a 15% premium to its three-year average, which may limit upside potential.

Financial Performance

In Q3 2026, McKesson reported revenue of $106.16 billion (+11.40% YoY), net income of $1.186 billion (+34.93% YoY), and EPS of $9.59 (+38.18% YoY). Gross margin improved to 3.46% (+1.47% YoY), reflecting strong operational performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are broadly positive, with multiple firms raising price targets recently. JPMorgan has the highest target at $1,107, and Barclays at $1,050. However, Wells Fargo and Mizuho maintain more cautious views with lower price targets and Neutral/Equal Weight ratings.

Wall Street analysts forecast MCK stock price to rise
14 Analyst Rating
Wall Street analysts forecast MCK stock price to rise
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 942.160
sliders
Low
880
Averages
942.83
High
1000
Current: 942.160
sliders
Low
880
Averages
942.83
High
1000
BofA
Buy
upgrade
$970
AI Analysis
2026-03-06
New
Reason
BofA
Price Target
$970
AI Analysis
2026-03-06
New
upgrade
Buy
Reason
BofA raised the firm's price target on McKesson (MCK) to $1,040 from $970 and keeps a Buy rating on the shares. McKesson "quietly" received a new National Drug Code for a biosimilar version of Neulasta a few weeks ago and while investors may be skeptical of McKesson's ambitions here, the firm frames "why this initial investor reaction could be wrong" based on seven large biosimilars coming to market over the next few years, including four that are directly addressable. The firm raised its McKesson target to reflect optionality on co-manufacturing and raised its Cencora (COR) target as well to reflect similar optionality.
Barclays
NULL
to
Overweight
maintain
$960
2026-02-18
Reason
Barclays
Price Target
$960
2026-02-18
maintain
NULL
to
Overweight
Reason
Barclays raised the firm's price target on McKesson to $1,050 from $960 and keeps an Overweight rating on the shares. The firm expects the stock to "remain in favor" as investors seek "pockets of safety within healthcare," but notes McKesson is now trading at a 15% premium to its three-year average.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MCK
Unlock Now

People Also Watch